Summary by Moomoo AI
Illumina, Inc., a leading company in the genomics industry, filed a Form 8-K with the U.S. Securities and Exchange Commission on January 4, 2024. The report announced the departure of Susan Tousi, the Chief Commercial Officer of Illumina, effective January 5, 2024. Following Tousi's departure, Bas Verhoef, currently Head of Region – Europe, will assume the role of Interim Chief Commercial Officer. The company's common stock is registered under the trading symbol ILMN on the NASDAQ. This executive change comes as part of the company's ongoing management adjustments and has been officially documented in the report signed by Charles E. Dadswell, General Counsel and Secretary of Illumina, Inc.